Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Bortezomib/dexamethasone"'
Autor:
Ting Niu, Steven Sun, Ming Qi, Yafei Wang, Weijun Fu, Jin Lu, Gang An, Xi-Nan Cen, Lijuan Chen, Maria-Victoria Mateos, Ajay K. Nooka, Jianda Hu, Jie Jin, Weiping Liu, Andrew Spencer, Xiao-Jun Huang, Wei Li, Xue Gai, Chengcheng Fu, Zhen Cai, Xue Yang, Katja Weisel, Zheng Ge
Publikováno v:
Blood. 136:38-41
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. In phase 3 clinical studies, the addition of daratumumab to standard-of-care regimens consistently demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b83f6f9c585b46e89e728562e398783
https://doi.org/10.1182/blood-2020-136108
https://doi.org/10.1182/blood-2020-136108
Autor:
Nawras Alshoubaki, Agnes K. Liman, Mohan Ramkumar, Andrew D. Liman, Roy Frye, Kevin Quann, Chaoyuan Kuang
Publikováno v:
Clinical Case Reports, Vol 8, Iss 10, Pp 1984-1987 (2020)
Clinical Case Reports
Clinical Case Reports
Patients with monoclonal gammopathy of renal significance should be treated with clone‐directed therapy against sources of monoclonal proteins in order to prevent progression to more advanced monoclonal gammopathies and renal failure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d176ff521a244b158687e3375045e9
https://doaj.org/article/979a27511e664c1b9d36d75dbb177f3d
https://doaj.org/article/979a27511e664c1b9d36d75dbb177f3d
Autor:
Paul G. Richardson, Tatiana Shelekhova, Iara Goncalves, Pierre Maison-Blanche, Chantana Polprasert, Sagar Lonial, Jacob P. Laubach, Jesús F. San-Miguel, Roman Hájek, Anna Sureda Balari, Ajai Chari, Mário Mariz, Ivan Spicka, Lutz Jacobasch, Philippe Moreau, Andrew Spencer, Vania Hungria, Meral Beksac, Meletios A. Dimopoulos, Joan Blade Creixenti, Tomasz Wróbel, Árpád Illés, S. Vincent Rajkumar, Ewa Lech-Marańda, Fredrik Schjesvold, Andre Abdo
Publikováno v:
Blood. 136:4-6
Background Panobinostat (Pano), a pan-histone deacetylase inhibitor, is approved for the treatment of relapsed or relapsed/refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone (FVd) in patients who have received ≥2 pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e28326e51c9548e03a77c57ad6c6147
https://doi.org/10.1182/blood-2020-140697
https://doi.org/10.1182/blood-2020-140697
Autor:
Lotfi Benboubker, Saad Z. Usmani, Shinsuke Iida, Jordan M. Schecter, Maria-Victoria Mateos, Christopher Chiu, Lisa O'Rourke, Ludek Pour, Michele Cavo, Nizar J. Bahlis, Gordon Cook, Jacob P. Laubach, Katja Weisel, Andrew Spencer, Sung-Soo Yoon, Ajay K. Nooka, Meletios A. Dimopoulos, Xiang Qin, Jon Ukropec
Publikováno v:
Haematologica
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db5dfa3798a904c49ea7da607f2926d
https://doi.org/10.3324/haematol.2019.217448
https://doi.org/10.3324/haematol.2019.217448
Autor:
Constantin Luca, Adina Ioana Bucur, Bianca Cerbu, Hortensia Ionita, Dan Costachescu, Ema-Cristina Borsi, Ovidiu Potre Oncu, Ioana Ionita, Cristina Potre Oncu
Publikováno v:
Revista de Chimie. 70:1017-1022
Multiple myeloma (MM) is typically sensitive to a range of cytotoxic agents, both as initial therapy and as relapsed disease treatment. Unfortunately, the responses are transient, and MM is not considered curable with the current approaches. This pap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0eaf131441be2a3e18027c0ae5fbea5f
https://doi.org/10.37358/rc.19.3.7053
https://doi.org/10.37358/rc.19.3.7053
Autor:
Stefano Rocco, D. Nappi, L. Catalano, F. Ferrara, G. Martinelli, Anna Emanuele Pareto, C. Cerchione, F. Pane, Salvatore Palmieri
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 22-(2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc59f4ceb8cc5816e5256d48f8d8a7ce
http://www.sciencedirect.com/science/article/pii/S2531137920301735
http://www.sciencedirect.com/science/article/pii/S2531137920301735
Autor:
Junichi Mukae, Takuya Komeno, Noriko Doki, Keisuke Tanaka, Atsushi Shinagawa, Takeshi Kobayashi, Kazuteru Ohashi, Takashi Kumagai, Megumi Akiyama, Naoki Wakimoto, Hiroshi Kojima, Daisuke Kudo, Shigeo Toyota, Yuichi Nakamura, Koh Yamamoto, Kazuhiko Kakihana, Tatsuya Saito, Hina Takano, Mitsuo Hori, Yuho Najima, Chikashi Yoshida, Masahide Yamamoto, Ikuyo Tsutsumi, Yasushi Okoshi, Takayuki Fujio, Aiko Igarashi
Publikováno v:
Acta Haematologica. 141:111-118
We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d71d61a8f7dd107cad7d93c96c5dfd04
https://doi.org/10.1159/000495338
https://doi.org/10.1159/000495338
Autor:
Marie Beaumont, Amandine Charbonnier, Magalie Joris, Berengere Gruson, Lavinia Merlusca, Jean-Pierre Marolleau, Vincent Marmouset
Publikováno v:
Hematological Oncology. 37:487-489
We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f575181c24e394909eec7fbedf1c94b0
https://doi.org/10.1002/hon.2671
https://doi.org/10.1002/hon.2671
Autor:
Kaya Miah, Christof Scheid, Christina Kunz, Stephan Kremers, Elias K. Mai, Mathias Haenel, Rolf Mahlberg, Jana Schlenzka, Markus Munder, Andreas Neubauer, Hartmut Goldschmidt, Katja Weisel, Ullrich Graeven, Igor Wolfgang Blau, Stefanie Huhn, Aneta Schieferdecker, Jan Dürig, Uwe M. Martens, Manfred Hensel, Dirk Hose, Anna Jauch, Roland Schroers, Peter Reimer, Christian Kunz, Andrea Seidel-Glaetzer, Uta Bertsch, Marc-Steffen Raab, Ivana von Metzler, Britta Besemer, Hans Salwender, Joerg Thomalla, Roland Fenk
Publikováno v:
Blood. 138:486-486
Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ef7d2483fc0ad83584b77135f23b97e
https://doi.org/10.1182/blood-2021-147323
https://doi.org/10.1182/blood-2021-147323
Autor:
Michael Pourdehnad, Anjan Thakurta, Patrick Hagner, Michael Amatangelo, Hsiling Chiu, Chad C Bjorklund, Archana Mukhopadhyay, Krista Wollerman, Jian Kang
Publikováno v:
Blood. 138:2669-2669
Background: Pomalidomide (POM) is an established agent in relapsed/refractory (R/R) multiple myeloma (MM). CC-92480, a novel cereblon E3 ligase modulator (CELMoD ®) agent, is being investigated in R/R MM patients in combination with the proteasome i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80336cd1a6ed965b9c568607fc137edc
https://doi.org/10.1182/blood-2021-153907
https://doi.org/10.1182/blood-2021-153907